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Disseminated malignant melanoma responds to chemother-
apy in approximately one-third of all cases. In the majority
of patients responses are partial and have little impact on
survival; subjective benefit of treatment was found to occur
in only half of the responding patients (Mulder et al., 1986).
The toxicity of combination chemotherapy applied to obtain
such responses is considerable, but the option of systemic
treatment cannot be ignored as in a combined series of 58
patients, there were two long-term survivors of this otherwise
fatal disease (Mulder et al., 1989). Therefore, it is worthwhile
to test alternatives to polychemotherapy in an effort to limit
toxicity and if possible to improve activity.
As an effect of a-interferon has been described in this
disease (Creagan et al., 1987), and DTIC remains the most
consistently effective agent available, we have combined the
two in the outpatients treatment of 31 patients with dissem-
inated malignant melanoma.
Eligible for treatment were patients with histologically pro-
ven disseminated malignant melanoma, who had not received
previous systemic therapy, had progressive disease, and gave
informed consent. Excluded were patients with evidence of
central nervous system metastasis on presentation, or uncon-
trolled other diseases.
Work-up consisted ofchest X-ray, echography or CT scan-
ning of the liver, bloodchemistry and physical examination
before every course and monthly in case of remission. Treat-
ment consisted of courses of 3 weeks consisting of daily
a-interferon-2a (Roferon, Hoffman-La Roche, The Nether-
lands) in a dose of 9 million units subcutaneously. In the first
3 days of the first course 3 million units were given. On the
first day of each course 750 mg m-2 DTIC (Dome, The
Netherlands) was given rapidly intravenously.
After two courses treatment was discontinued in patients
with progressive disease. After four courses treatment was
extended to six courses only in responding patients. After six
courses all treatment was stopped. Paracetamol was presc-
ribed routinely to suppress fever in the first week, and after-
wards it was given if necessary.
Dose modification consisted of giving interferon on alter-
nating days as long as necessary to alleviate symptoms of
toxicity, and 25% dose reduction of DTIC in case of grade
three or more haematological toxicity, or nausea.
Evaluation of toxicity followed the WHO guide lines
(WHO Handbook 1979). A complete response was defined as
the complete disappearance of all signs of disease, a partial
response as the decrease in the sum of the product of perpen-
dicular diameters of all measurable tumour lesion of at least
50%, without progression of any lesion or development of
new lesions. A response had to last a minimum of I month.
Progressive disease was defined as an increase in the product
of parameters of more than 25%, or formation of new
lesions.
A total number of 107 courses was given to 31 consecutive
patients. Eighteen patients were male, 13 female. Median age
was 51 (range 17-74) years.
Nine patients had less than four lesions identified and no
lesion larger than 3 cm (limited volume). All patients had a
Karnofsky performance score of 70 or above. Main sites of
disease are given in Table I.
Toxicity, mainly fatigue, required temporary dose reduc-
tion of interferon in two patients, while one patient stopped
treatment. Four patients had weight loss over the treatment
period of 5% of total body weight or more. In addition to
toxicity graded in Table II, five patients had muscle aches in
the first week of treatment, four patients had fever despite
the use of paracetamol, one patient had joint pains and one
patient had psychological depression possibly related to
interferon. All patients had nausea and vomiting on DTIC,
in one patient this was severe requiring dose reduction, in
one patient DTIC was reduced because ofthrombocytopenia.
Three patients therefore had dose adjustment of interferon
and one of both drugs (13%).
Eight patients developed symptomatic brain metastases
during treatment. One of these died during the first course
and was not evaluable for response. Nineteen patients had
progressive disease, 11 patients had a response, three of
which were complete. Response sites are given in Table 1.
Complete responses lasted for 16 +, 7 and 5 + months. The
relapsing patient from this CR group had a brain metastasis
without signs of systemic relapse. Partial responses lasted for
1, 1, 3, 4, 5 +, 6, 8 and 9 months. Seven responding patients
had high and four low volume disease, seven were male and
four female. Median survival was 6 months for the whole
group.
The response rate of DTIC/a-interferon combination as
given in this study was 35% (95% confidence interval
19-55%). The complete response rate is 10% (2-25%).
These rates are somewhat above those expected with DTIC
alone (McClay & Mastrangelo, 1988) or with interferon
Table I Sites ofdisease and response (more than one site involved per
patient)
Main sites ofdisease Site ofresponses
Cutaneous 5
Liver 6
Lung 14 6
Subcutaneous 19 8
Lymph nodes 3
Mucosal I
Adrenal I
Bone 2
Spleen I
Table 11 Haematological toxicity (WHO grading)
WHO grade
0 1 2 3 4
Leukopenia 72 16 8 4 0
Thrombopenia 98 0 0 2 0
Values are percentages of courses, n = 107.
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alone (Creagan et al., 1987), and are comparable with the
results of polychemotherapy (Mulder et al., 1986; Mulder et
al., 1989; McClay & Mastrangelo, 1988). Moreover, these
response rates for the combination DTIC and interferon have
been found to be reproducible in other studies (Thomson et
al., 1987; Guillou et al., 1989), as has been the occurrence of
occasional long-term responses. The same response percen-
tage of the combination (39%) was seen in a controlled study
comparing it to DTIC alone (15%) (Vorobriof et al., 1989).
The spectrum of responding lesions also resembles that de-
scribed previously for polychemotherapy (Mulder et al.,
1989). Responses occurred mainly in subcutaneous nodules
and in lung metastases, but not in the liver. Patients with low
volume disease seem to fare better than others.
In comparison to polychemotherapy this two drug regimen
has less toxicity, especially when the DTIC related nausea
and vomiting is mitigated by the new serotonin antagonists.
The interferon dosage chosen in this study was acceptable
without dose adjustment for 87% of patients. Of importance
is the fairly rapid manifestation of responses, always within
the first month of treatment. Responses then continued in
large lesions until the fourth or fifth course. This regimen is
clearly inactive for brain metastases in view of the 25%
incidence of central nervous system manifestations even in
the presence of systemic partial or complete remissions. The
emergence of drugs active in melanoma and penetrating the
blood-brain barrier, such as Fotemustine (Khayat et al.,
1987), could add significantly to the outcome of chemo-
therapy in metastatic melanoma.
In view of the manageable toxicity of the regimen de-
scribed here, its combination with such drugs should be
contemplated, especially for patients with disease sites likely
to respond to treatment, such as lung and subcutaneous
metastases. Furthermore, controlled studies, focusing on sur-
vival and quality of life, should be initiated, comparing no
therapy or treatment with DTIC alone with the combination
of DTIC and interferon described here.
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